SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Among these, GLP-1RAs and SGLT2 inhibitors are frequently used in daily clinical practice, but it is important to establish a treatment strategy for NAFLD that is poorly managed even under the use of these agents.